<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002026</url>
  </required_header>
  <id_info>
    <org_study_id>033A</org_study_id>
    <secondary_id>179</secondary_id>
    <nct_id>NCT00002026</nct_id>
  </id_info>
  <brief_title>Treatment and Suppression of Hairy Leukoplakia in ARC Patients With Oral Acyclovir (ACV)</brief_title>
  <official_title>Treatment and Suppression of Hairy Leukoplakia in ARC Patients With Oral Acyclovir (ACV)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glaxo Wellcome</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of oral acyclovir for the treatment and suppression of Epstein-Barr&#xD;
      virus (EBV) related hairy leukoplakia (HL). To determine the long-term safety of acyclovir in&#xD;
      the AIDS-related complex (ARC) patient with HL. To monitor the progression of HIV disease in&#xD;
      the HL patient and compare to existing historical control data.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Leukoplakia, Hairy</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acyclovir</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Topical antifungal therapy.&#xD;
&#xD;
        Patient must have:&#xD;
&#xD;
          -  Newly diagnosed clinical and histological hairy leukoplakia.&#xD;
&#xD;
          -  Positive HIV antibody by licensed ELISA or Western blot.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with AIDS or a history of intolerance or allergy to acyclovir are excluded.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded within 2 weeks of study entry:&#xD;
&#xD;
          -  Systemic antifungal treatment.&#xD;
&#xD;
          -  Excluded within 6 weeks of study entry:&#xD;
&#xD;
          -  Immunomodulators.&#xD;
&#xD;
          -  Systemic antiviral treatment.&#xD;
&#xD;
        Patients with AIDS or a history of intolerance or allergy to acyclovir are excluded.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded within 2 weeks of study entry:&#xD;
&#xD;
          -  Systemic antifungal.&#xD;
&#xD;
          -  Excluded within 6 weeks of study entry:&#xD;
&#xD;
          -  Immunomodulators.&#xD;
&#xD;
          -  Systemic antiviral treatment.&#xD;
&#xD;
          -  Excluded within 8 weeks of study entry:&#xD;
&#xD;
          -  Zidovudine (AZT) or other antiretroviral therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Univ of Southern California / LA County USC Med Ctr</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>900331079</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Herbst JS, Morgan J, Raab-Traub N, Resnick L. Comparison of the efficacy of surgery and acyclovir therapy in oral hairy leukoplakia. J Am Acad Dermatol. 1989 Oct;21(4 Pt 1):753-6. doi: 10.1016/s0190-9622(89)70250-4.</citation>
    <PMID>2808791</PMID>
  </reference>
  <verification_date>May 1990</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>AIDS-Related Opportunistic Infections</keyword>
  <keyword>Leukoplakia, Oral</keyword>
  <keyword>Herpesvirus 4, Human</keyword>
  <keyword>Acyclovir</keyword>
  <keyword>AIDS-Related Complex</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukoplakia, Hairy</mesh_term>
    <mesh_term>Leukoplakia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acyclovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

